Summary of Preclinical Drug
Research: Partim Delputte
geschreven door
Bi0med
www.stuvia.com
Gedownload door: InnePatteet |
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar.
, Stuvia - Koop en Verkoop de Beste Samenvattingen
Biopharmaceuticals: prof. Delputte
WHAT ARE BIOPHARMACEUTICALS?
For example EPO, insulin, vaccines, mAb,…
1. Protein-like structures
2. Oligonucleotides
3. Sugars / glycans
a. Usually not used: too complex & usually low
affinity to targets: side effects
4. Cell-typing
a. Isolate cells from patients, treat them and inject them again
Biopharmaceuticals are VALUABLE. You can have novel innovative therapies for significant unmet
medical needs. It is a radically new approach. 1/3 – ½ of all drugs in development are
biopharmaceuticals.
- NME = new molecular entity = when a small molecule goes into development
- NBE = new biological entity
Advantages !!!
Inherently highly specific for the target
Minimum risk for non-mechanism based toxicity and safety
Capable of increasing growth factors, hormones, enzymes…
Can modulate protein/protein interactions that cannot be targeted by small molecules
Applicability in multiple therapeutic areas and for multiple targets
Value
o Larger profits for companies
o Therapeutic value
Definition
Small molecules are usually taken orally, while biopharmaceuticals are mostly administered IV.
The term biopharmeuticals is widely used, but is hardly ever defined by its users, definitions of
biopharmaceuticals in common use vary greatly.
- Pharmaceutical: involves chemical (non-biological) medicinal products manufactured using
chemical sources and processes.
- Biopharmaceutical: involves inherently biological products with manufacture involving
biological sources and processes
= Everything that living organisms can make: proteins, nucleic acids, glycans, viruses, bacteria,
vaccines, cell-based therapies…
Problem of antisera / antibodies = we make antibodies against the antibodies of the horse.
Antivenom usually only works once. Also biologicals are unstable and difficult to store.
Gedownload door: InnePatteet |
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar.
Research: Partim Delputte
geschreven door
Bi0med
www.stuvia.com
Gedownload door: InnePatteet |
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar.
, Stuvia - Koop en Verkoop de Beste Samenvattingen
Biopharmaceuticals: prof. Delputte
WHAT ARE BIOPHARMACEUTICALS?
For example EPO, insulin, vaccines, mAb,…
1. Protein-like structures
2. Oligonucleotides
3. Sugars / glycans
a. Usually not used: too complex & usually low
affinity to targets: side effects
4. Cell-typing
a. Isolate cells from patients, treat them and inject them again
Biopharmaceuticals are VALUABLE. You can have novel innovative therapies for significant unmet
medical needs. It is a radically new approach. 1/3 – ½ of all drugs in development are
biopharmaceuticals.
- NME = new molecular entity = when a small molecule goes into development
- NBE = new biological entity
Advantages !!!
Inherently highly specific for the target
Minimum risk for non-mechanism based toxicity and safety
Capable of increasing growth factors, hormones, enzymes…
Can modulate protein/protein interactions that cannot be targeted by small molecules
Applicability in multiple therapeutic areas and for multiple targets
Value
o Larger profits for companies
o Therapeutic value
Definition
Small molecules are usually taken orally, while biopharmaceuticals are mostly administered IV.
The term biopharmeuticals is widely used, but is hardly ever defined by its users, definitions of
biopharmaceuticals in common use vary greatly.
- Pharmaceutical: involves chemical (non-biological) medicinal products manufactured using
chemical sources and processes.
- Biopharmaceutical: involves inherently biological products with manufacture involving
biological sources and processes
= Everything that living organisms can make: proteins, nucleic acids, glycans, viruses, bacteria,
vaccines, cell-based therapies…
Problem of antisera / antibodies = we make antibodies against the antibodies of the horse.
Antivenom usually only works once. Also biologicals are unstable and difficult to store.
Gedownload door: InnePatteet |
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar.
